Narrative review / 2013
Medical therapies including GnRH agonists and agents like epigallocatechin gallate have shown efficacy for fibroid regression and symptom relief in trials.
This review examined literature from PubMed and Google Scholar up to June 2012 regarding the pathophysiology and medical treatments of uterine leiomyoma. Multiple pathogenetic factors, including genetics, estrogens, progesterone, and growth factors, are implicated in fibroid development. While GnRH agonists are FDA-approved to reduce fibroid volume and symptoms, compounds such as mifepristone, asoprisnil, ulipristal acetate, and epigallocatechin gallate have demonstrated effectiveness for fibroid regression and symptom improvement in clinical trials.
- Study type
- Narrative review
- Who was studied
- Women with uterine leiomyoma (fibroids)
- What was measured
- Pathophysiology and medical treatments for uterine leiomyoma
THE PAPER
Uterine leiomyoma: available medical treatments and new possible therapeutic options.
Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, Castellucci M, Ciarmela P. J Clin Endocrinol Metab, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.